Analysts say pharma may escape near-term hit from Trump tariffs

Analysts say pharma may escape near-term hit from Trump tariffs

Drug giants’ internal allocation of value – or “transfer pricing” – will be key to how hard the pharma sector is hit by Donald Trump’s expected tariffs, according to analysis from Bank of America Merrill Lynch.

FTSE 100 pharma giants GSK and Astrazeneca appear to swerve Trump tariffs

FTSE 100 pharma giants GSK and Astrazeneca may have escaped the worst of US President Donald Trump’s tariffs, according to a City broker. Pharmaceutical goods appear to be exempt from higher-rate tariffs introduced by President Trump in his Rose Garden ‘Liberation Day’ address on Wednesday, but there is still uncertainty about the impact on the sector.  This is according to a new research note from Shore Capital, which has spoken to FTSE 100-lis…

FTSE 100 pharma giants GSK and Astrazeneca may have dodged Trump tariffs

Pharmaceutical goods appear to be exempt from higher-rate tariffs introduced by President Trump in his 'Liberation Day' address on Wednesday, according to a City broker

Analyst: Donald Trump ‘playing his hand at the poker table’

Share via: Facebook X LinkedIn WhatsApp Pocket Messenger Copy Link Telegram Email More Jochen Stanzl, chief market analyst at CMC Markets, warns that President Trump is making a bold gambleRead More...